-
公开(公告)号：KR100879636B1
公开(公告)日：2009-01-21
申请号：KR1020070084322
申请日：2007-08-22
Applicant: 한국과학기술연구원
IPC: A61K31/517 , A61P25/00
CPC classification number: A61K31/517 , A61K31/5377
Abstract: A pharmaceutical composition for preventing and treating the disease related to the central nervous system, and a food composition are provided to obtain the effect on emesis, nausea, alcoholism, drugs abuse, depression, compulsion neurosis, anxiety, etc. A pharmaceutical composition for preventing and treating the disease related to the central nervous system comprises a quinoline derivative compound represented by the formula 1 or its pharmaceutically acceptable salt as an active ingredient, wherein R1 is H, a C1-C6 alkyl group, a phenyl group or a benzyl group; R2 is a heterocyclic group selected from morpholine, pyrrolidine and piperidine; the phenyl group or the benzyl group can be substituted with a substituent selected from a halogen atom, a C1-C6 alkyl group and a C1-C6 alkoxy group; and n is an integer of 1-6.
Abstract translation: 提供了用于预防和治疗与中枢神经系统有关的疾病的药物组合物和食物组合物，以获得对呕吐，恶心，酒精中毒，药物滥用，抑郁，强迫性神经症，焦虑等的作用。 并且治疗与中枢神经系统相关的疾病包括由式1表示的喹啉衍生物化合物或其药学上可接受的盐作为活性成分，其中R1是H，C1-C6烷基，苯基或苄基; R2是选自吗啉，吡咯烷和哌啶的杂环基; 苯基或苄基可以被选自卤素原子，C1-C6烷基和C1-C6烷氧基的取代基取代; n为1-6的整数。
-
公开(公告)号：KR100882925B1
公开(公告)日：2009-02-10
申请号：KR1020070058542
申请日：2007-06-14
Applicant: 한국과학기술연구원
IPC: A61K31/415 , A61K31/496 , A61P25/00
CPC classification number: A61K31/496
Abstract: 본 발명은 세로토닌 5-HT
3 A에 대한 길항 활성 효과를 나타내어 구토증(emesis), 메스꺼움증(nausea), 알콜중독증, 약물남용증, 우울증, 강박노이로제, 불안증(anxiety), 발작, 알츠하이머형 치매, 파킨슨병, 헌팅턴 무도병(Huntington's chorea), 정신병(psychosis), 정신분열증, 자살성향(suicidal tendency), 수면장애(sleep disorders), 식욕장애(appetite disorders) 및 편두통 등의 중추신경계 질환의 예방 및 치료제로서 유용한 피라졸 유도체를 유효성분으로 함유하는 약제 조성물에 관한 것이다.
세로토닌 5-ＨＴ₃Ａ 길항제, 피라졸 유도체, 구토, 알콜 중독, 약물 남용, 강박증, 우울증-
公开(公告)号：KR1020080110152A
公开(公告)日：2008-12-18
申请号：KR1020070058542
申请日：2007-06-14
Applicant: 한국과학기술연구원
IPC: A61K31/415 , A61K31/496 , A61P25/00
CPC classification number: A61K31/496
Abstract: A pharmaceutical composition comprising pyrazole derivative having antagonistic effects against serotonin 5-HT3A(5-hydroxytryptamine(serotonin) receptor 3A) is provided to improve the inhibitory activity and bonding activity about 5-HT3A, thereby being applicable to the therapeutic agent of the central nervous system disease. The pharmaceutical composition for prevention and treatment of the central nervous system disease associated with serotonin 5-HT3A receptor comprises the pyrazole derivative compound and pharmaceutically acceptable salts, wherein the central nervous system disease is selected from emesis. nausea, alcoholism, drugs abuse, depression, compulsion neurosis, anxiety, seizure, Alzheimer type dementia, Parkinson's disease, Huntington`s chorea, psychosis, schizophrenia, suicidal tendency, somnopathy(sleep disorders), appetite disorder and migraine.
Abstract translation: 提供了包含对5-羟色胺5-HT3A（5-羟色胺）受体3A具有拮抗作用的吡唑衍生物的药物组合物，以提高关于5-HT3A的抑制活性和结合活性，从而适用于中枢神经的治疗剂 系统疾病 用于预防和治疗与5-羟色胺5-HT 3 A受体相关的中枢神经系统疾病的药物组合物包括吡唑衍生物化合物和药学上可接受的盐，其中中枢神经系统疾病选自呕吐。 恶心，酒精中毒，药物滥用，抑郁症，强迫性神经症，焦虑症，癫痫发作，阿尔茨海默氏型痴呆，帕金森病，亨廷顿舞蹈病，精神病，精神分裂症，自杀倾向，睡眠障碍（睡眠障碍），食欲障碍和偏头痛。
-
-
Search Results
3
records
(took 0.018 seconds)
